You are here: Home > Investor Relations

 Investor Relations

 
 Recent Releases

 Archived Releases

 Annual Meeting

 Analyst Coverage

 Corporate Governance

 SEC Filings

 XBRL Interactive Data
 Files


 Transfer Agent

 Auditors

 E-Mail Alerts
 
 Contact Us

12/16/2014 Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation

12/3/2014 ELITE PHARMACEUTICALS REPORTS SUCCESSFUL PIVOTAL BIOEQUIVALENCE STUDY FOR ABUSE-DETERRENT OXYCODONE PRODUCT ELI-201

11/14/2014 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
Revenues increase by 8%
Conference Call Scheduled for Wednesday, November 19 at 11:00 AM EST


10/24/2014 ELITE PHARMACEUTICALS ANNOUNCES NEW MANAGEMENT APPOINTMENTS

9/9/2014 ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT
HAL study compared subjective effects of drug liking, drug high and good drug effects between ELI-200 and the comparator formulation in non-dependent recreational drug users


More Releases...

Click Here for a complete archive


Elite Pharmaceuticals, Inc. 165 Ludlow Ave., Northvale, NJ 07647    Phone:  201-750-2646  Fax:  201-750-2755 
E Mail:  webmaster@elitepharma.com